This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.

The UK's FTSE 100 index showed a modest gain, driven by healthcare and consumer shares. However, concerns over upcoming ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Harvey Jones takes a look at 2 FTSE 100 income stocks that investors are snubbing right now to see whether there's a big ...

(Alliance News) - GSK PLC on Monday said its gepotidacin drug has been accepted for priority review in the US as an oral option for the treatment of a form of sexually transmitted infection gonorrhoea ...

As of 0715 GMT, the blue-chip index FTSE 100 gained 0.3% and the British pound rose 0.09% against the dollar to above 1.34.

Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.

More than 600,000 cases of gonorrhoea were reported in the U.S. in 2023, according to the U.S. Centers for Disease Control and Prevention. There are no vaccine licenses in the U.S. for preventing the ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...